Osteogenic commitment of Wharton's jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application

Background: Orthopaedic diseases are one of the major targets for regenerative medicine. In this context, Wharton’s jelly (WJ) is an alternative source to bone marrow (BM) for allogeneic transplantation since its isolation does not require an invasive procedure for cell collection and does not raise...

ver descrição completa

Detalhes bibliográficos
Autores: Cabrera Pérez, Raquel, Monguió Tortajada, Marta, Gámez Valero, Ana, Rojas Márquez, Raquel, Borràs, Francesc Enric, Roura, Santiago, Vives, Joaquim
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2019
País:España
Recursos:Universitat Pompeu Fabra
Repositorio:Repositorio Digital de la UPF
OAI Identifier:oai:repositori.upf.edu:10230/44192
Acesso em linha:http://hdl.handle.net/10230/44192
http://dx.doi.org/10.1186/s13287-019-1450-3
Access Level:acceso abierto
Palavra-chave:Mesenchymal stromal cells
Bone marrow
Wharton’s jelly
Osteogenic differentiation
Bone regeneration
id ES_0c153381f2ca47caeb10ffd932d5bd74
oai_identifier_str oai:repositori.upf.edu:10230/44192
network_acronym_str ES
network_name_str España
repository_id_str
spelling Osteogenic commitment of Wharton's jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical applicationCabrera Pérez, RaquelMonguió Tortajada, MartaGámez Valero, AnaRojas Márquez, RaquelBorràs, Francesc EnricRoura, SantiagoVives, JoaquimMesenchymal stromal cellsBone marrowWharton’s jellyOsteogenic differentiationBone regenerationBackground: Orthopaedic diseases are one of the major targets for regenerative medicine. In this context, Wharton’s jelly (WJ) is an alternative source to bone marrow (BM) for allogeneic transplantation since its isolation does not require an invasive procedure for cell collection and does not raise major ethical concerns. However, the osteogenic capacity of human WJ-derived multipotent mesenchymal stromal cells (MSC) remains unclear. Methods: Here, we compared the baseline osteogenic potential of MSC from WJ and BM cell sources by cytological staining, quantitative real-time PCR and proteomic analysis, and assessed chemical and biological strategies for priming undifferentiated WJ-MSC. Concretely, different inhibitors/activators of the TGFβ1-BMP2 signalling pathway as well as the secretome of differentiating BM-MSC were tested. Results: Cytochemical staining as well as gene expression and proteomic analysis revealed that osteogenic commitment was poor in WJ-MSC. However, stimulation of the BMP2 pathway with BMP2 plus tanshinone IIA and the addition of extracellular vesicles or protein-enriched preparations from differentiating BM-MSC enhanced WJ-MSC osteogenesis. Furthermore, greater outcome was obtained with the use of conditioned media from differentiating BM-MSC. Conclusions: Altogether, our results point to the use of master banks of WJ-MSC as a valuable alternative to BM-MSC for orthopaedic conditions.BioMed Central202020202019info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/44192http://dx.doi.org/10.1186/s13287-019-1450-3reponame:Repositorio Digital de la UPFinstname:Universitat Pompeu FabraInglésStem Cell Res Ther. 2019; 10(1):356© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.http://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repositori.upf.edu:10230/441922026-06-12T07:21:37Z
dc.title.none.fl_str_mv Osteogenic commitment of Wharton's jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application
title Osteogenic commitment of Wharton's jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application
spellingShingle Osteogenic commitment of Wharton's jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application
Cabrera Pérez, Raquel
Mesenchymal stromal cells
Bone marrow
Wharton’s jelly
Osteogenic differentiation
Bone regeneration
title_short Osteogenic commitment of Wharton's jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application
title_full Osteogenic commitment of Wharton's jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application
title_fullStr Osteogenic commitment of Wharton's jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application
title_full_unstemmed Osteogenic commitment of Wharton's jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application
title_sort Osteogenic commitment of Wharton's jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application
dc.creator.none.fl_str_mv Cabrera Pérez, Raquel
Monguió Tortajada, Marta
Gámez Valero, Ana
Rojas Márquez, Raquel
Borràs, Francesc Enric
Roura, Santiago
Vives, Joaquim
author Cabrera Pérez, Raquel
author_facet Cabrera Pérez, Raquel
Monguió Tortajada, Marta
Gámez Valero, Ana
Rojas Márquez, Raquel
Borràs, Francesc Enric
Roura, Santiago
Vives, Joaquim
author_role author
author2 Monguió Tortajada, Marta
Gámez Valero, Ana
Rojas Márquez, Raquel
Borràs, Francesc Enric
Roura, Santiago
Vives, Joaquim
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv Mesenchymal stromal cells
Bone marrow
Wharton’s jelly
Osteogenic differentiation
Bone regeneration
topic Mesenchymal stromal cells
Bone marrow
Wharton’s jelly
Osteogenic differentiation
Bone regeneration
description Background: Orthopaedic diseases are one of the major targets for regenerative medicine. In this context, Wharton’s jelly (WJ) is an alternative source to bone marrow (BM) for allogeneic transplantation since its isolation does not require an invasive procedure for cell collection and does not raise major ethical concerns. However, the osteogenic capacity of human WJ-derived multipotent mesenchymal stromal cells (MSC) remains unclear. Methods: Here, we compared the baseline osteogenic potential of MSC from WJ and BM cell sources by cytological staining, quantitative real-time PCR and proteomic analysis, and assessed chemical and biological strategies for priming undifferentiated WJ-MSC. Concretely, different inhibitors/activators of the TGFβ1-BMP2 signalling pathway as well as the secretome of differentiating BM-MSC were tested. Results: Cytochemical staining as well as gene expression and proteomic analysis revealed that osteogenic commitment was poor in WJ-MSC. However, stimulation of the BMP2 pathway with BMP2 plus tanshinone IIA and the addition of extracellular vesicles or protein-enriched preparations from differentiating BM-MSC enhanced WJ-MSC osteogenesis. Furthermore, greater outcome was obtained with the use of conditioned media from differentiating BM-MSC. Conclusions: Altogether, our results point to the use of master banks of WJ-MSC as a valuable alternative to BM-MSC for orthopaedic conditions.
publishDate 2019
dc.date.none.fl_str_mv 2019
2020
2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/44192
http://dx.doi.org/10.1186/s13287-019-1450-3
url http://hdl.handle.net/10230/44192
http://dx.doi.org/10.1186/s13287-019-1450-3
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Stem Cell Res Ther. 2019; 10(1):356
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv BioMed Central
publisher.none.fl_str_mv BioMed Central
dc.source.none.fl_str_mv reponame:Repositorio Digital de la UPF
instname:Universitat Pompeu Fabra
instname_str Universitat Pompeu Fabra
reponame_str Repositorio Digital de la UPF
collection Repositorio Digital de la UPF
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403264315817984
score 15,81155

Registos relacionados